Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Financial Officer | February 22, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date February 22, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $119.49 · Expires 2031-02-22 | Direct | 32,000 |
Reported balance
After 2021-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-22 · Grant · Acquired 32,000 · Balance 32,000 F1: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENVEC INC
Report date June 16, 2017 · Filed June 20, 2017
Section 16 reporting ended · disclosed 2017-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,050 |
Reported balance
After 2017-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-06-16 · Exercise / conversion · Acquired 1,500 · Balance 9,050 |
| Common StockSEC Table I · non-derivative | Direct | 8,257 |
Reported balance
After 2016-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-06-16 · Tax withholding · Disposed 793 · Balance 8,257 F1: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2017-06-16 · Disposition to issuer · Disposed 8,257 · Balance 0 F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2017-06-16 | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-16 · Exercise / conversion · Disposed 1,500 · Balance 0 F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations.
F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration").
F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2021 Filed Feb 23, 2021 18:32 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $119.49 | $0.00 |
DisclosureSEC source: 0000899243-21-007763 · doc4.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 22:02 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $91.79 | $0.00 |
DisclosureSEC source: 0000899243-20-007218 · doc4.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-03-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2021) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $127.96 | $0.00 |
DisclosureSEC source: 0000899243-19-007017 · doc4.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 7, 2020) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option · Derivative | 2,734 | $0.00 Strike: $61.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008437 · edgar.xml · derivative · entry 5 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,640 Underlying: Common Stock · 2,734 shares Expires 2025-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option · Derivative | 5,223 | $0.00 Strike: $99.75 | $0.00 |
DisclosureSEC source: 0001179110-18-008437 · edgar.xml · derivative · entry 4 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205 Underlying: Common Stock · 5,223 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 10,099 | $287.46 | $2,903,058.54 |
DisclosureSEC source: 0001179110-18-008437 · edgar.xml · nonDerivative · entry 3 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,668 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,734 | $61.60 | $168,414.40 |
DisclosureSEC source: 0001179110-18-008437 · edgar.xml · nonDerivative · entry 2 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 19:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,223 | $99.75 | $520,994.25 |
DisclosureSEC source: 0001179110-18-008437 · edgar.xml · nonDerivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $124.45 | $0.00 |
DisclosureSEC source: 0001179110-18-003407 · edgar.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2019) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:33 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionStock Options (right to buy) · Derivative | 1,500 | $3.80 Strike: $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001161 · edgar.xml · derivative · entry 4 Schneebaum Marc R · CIK 0001396871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2017-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:33 UTC | GENVEC INC GNVC · Entity 175088 | Disposition to issuerCommon Stock | 8,257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-17-001161 · edgar.xml · nonDerivative · entry 3 Schneebaum Marc R · CIK 0001396871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3 · shares: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4 · price: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:33 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionCommon Stock | 1,500 | $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001161 · edgar.xml · nonDerivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 20:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 27,300 | $0.00 Strike: $15.80 | $0.00 |
DisclosureSEC source: 0001179110-17-003950 · edgar.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 Underlying: Common Stock · 27,300 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 2, 2018) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 16:45 UTC | GENVEC INC GNVC · Entity 175088 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001140361-16-083402 · doc1.xml · derivative · entry 1 Schneebaum Marc R · CIK 0001396871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-10-20 Read SEC document |
| June 16, 2016 Filed Jun 20, 2017 16:33 UTC | GENVEC INC GNVC · Entity 175088 | Tax withholdingCommon Stock | 793 | $7.19 | $5,701.67 |
DisclosureSEC source: 0001123292-17-001161 · edgar.xml · nonDerivative · entry 2 Schneebaum Marc R · CIK 0001396871 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,257 F1 · kind: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.